ReviewCurrent atherosclerosis reports2022
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women.
Review in Current atherosclerosis reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Polypharmacy and Drug-Drug Interaction Architecture in Hospitalized Cardiovascular Patients: Insights from Real-World Analysis.Biomedicines · 2026Article
- Challenges in the prevention, treatment and management of cardiovascular disease among older adults.The Lancet regional health. Europe · 2025Review
- Polypharmacy and self-medication among older adults in Indian urban communities-a cross-sectional study.Scientific reports · 2025Article
- Categorical Analysis of Database Consistency in Reporting Drug-Drug Interactions for Cardiovascular Diseases.Pharmaceutics · 2024Article
- Prescribing Practices in Geriatric Patients with Cardiovascular Diseases.International journal of environmental research and public health · 2022Article
- Polypharmacy, Unintended Consequences, and Impact of Lifestyle Medicine.American journal of lifestyle medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe intent of this review is to provide an update in polypharmacy in older adults and women with a focus on common determinants and strategies to mitigate polypharmacy. RECENT
findingsPolypharmacy is becoming a critical focus in the management of cardiovascular diseases. It may emerge unintentionally while managing multimorbidity in older adults or in the vulnerable subgroup of patients, such as pregnant and lactating females. Clinicians should utilize several approaches such as deprescribing, sex-specific risk assessment, and encouraging healthy lifestyle to minimize inappropriate and unnecessary use of medications. A shared decision-making model along with coordination and collaboration among healthcare providers should be utilized in the selection and management of pharmacotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.